Skip to main content
Institutional profile

Novartis

Novartis is one of the world’s leading innovative pharmaceutical companies, with a focused strategy around prescription medicines, specialty care, and advanced therapeutic platforms. Following its strategic simplification and separation from non-core businesses, Novartis has increasingly emphasized high-value innovative medicines in areas such as oncology, immunology, neuroscience, cardiovascular disease, and radioligand therapy.

  • Highest 2026 tier: Tier I
  • Global Pharmaceutical Companies
  • 3 ranking categories

Overview

Novartis is one of the world’s leading innovative pharmaceutical companies, with a focused strategy around prescription medicines, specialty care, and advanced therapeutic platforms. Following its strategic simplification and separation from non-core businesses, Novartis has increasingly emphasized high-value innovative medicines in areas such as oncology, immunology, neuroscience, cardiovascular disease, and radioligand therapy.

The company’s strength lies in its balanced portfolio and scientific breadth. Novartis has major capabilities in small molecules, biologics, cell therapy, gene therapy-related areas, and radioligand therapy. Its cardiovascular and oncology franchises remain particularly important, while its immunology and neuroscience programs provide additional long-term growth opportunities.

Novartis is included in 3 2026 ranking categories. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.

Firm facts

Public identityNovartis
Founded1996
Institution typeGlobal Pharmaceutical Companies institution
HeadquartersBasel, Switzerland
Primary focusGlobal Pharmaceutical Companies
Highest 2026 ranking tierTier I

Principal activities

The company’s strength lies in its balanced portfolio and scientific breadth. Novartis has major capabilities in small molecules, biologics, cell therapy, gene therapy-related areas, and radioligand therapy. Its cardiovascular and oncology franchises remain particularly important, while its immunology and neuroscience programs provide additional long-term growth opportunities.

Core capability

Global Pharmaceutical Companies

Client relevance

Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.

Execution and verification

Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.

Sector and mandate coverage

Primary category

Global Pharmaceutical Companies

Institutional context

Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.

Market position

Novartis’ global reach, focused innovative medicines strategy, therapeutic breadth, and investment in advanced treatment platforms support its position among the leading global pharmaceutical companies.

Novartis is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.

Competitive context

The relevant peer set varies by category, geography, client segment and mandate. Novartis should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.

Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.

Leadership and governance

Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.

Corporate and public information

The public-facing organization is identified here as Novartis. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.

Corporate and disclosure information
OrganizationNovartis
HeadquartersBasel, Switzerland
Verification noteConfirm legal entity, licenses, offices and engagement terms directly before appointment or use.

Additional published ranking appearances

These entries retain the edition, classification and assessed business name published in the source. Historical entries describe that edition, including businesses whose ownership or name later changed.

Published rankingEdition / tierAssessed business
Top 20 Global Pharmaceutical Companies 20252025 · Tier INovartis
Top 20 Global Pharmaceutical Companies 20242024 · Tier INovartis
Top 20 Global Pharmaceutical Companies 20232023 · Tier INovartis

Rankings and recognition

2026

Tier I

2026

Tier I

2026

Tier III

Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.

Related Economy analysis

Further sector analysis:

Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:

Sources and data transparency

Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.

  1. Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
  2. Healthcare Ranking — Top 30 Global Pharmaceutical Companies 2026 — 2026 inclusion and tier classification.
  3. Healthcare Ranking — Top 30 Vaccine & Immunotherapy Developers 2026 — 2026 inclusion and tier classification.
  4. The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
  5. The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
  6. The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.

Corrections and Updates

Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.

First published: 29 August 2026

Last substantively reviewed: 29 August 2026

Profile scope: Global Pharmaceutical Companies

This profile has been compiled from publicly available institutional and editorial sources. The profiled organization does not determine its inclusion, editorial characterization or ranking status.

Rankings and recognition — 2027

Recorded appearances in The Economy Rankings. Each entry concerns the assessed business, product, institution or workforce scope in the linked edition.

RankingEdition / classificationAssessed scope
Employers for Graduate Careers2027 · Tier IIIBasel, Switzerland: postgraduate Technical Research and Development Biologics employee pathway.
Employers for Internal Career Mobility2027 · Tier IIDirect employees in the documented internal career pathways; external recruits, customers and contractors excluded.
Employers for Workforce Reskilling2027 · Tier IIIDirect employees in the documented programme or operating population; country, role and eligibility conditions retained.
Employers for Parental Leave2027 · Tier IIIGreat Britain employees covered by the published policy; contractors excluded
Employers for Hybrid Work2027 · Tier IIINovartis Pharmaceuticals UK hybrid professional employees.
Employers for Employee Participation2027 · Tier IIIDirect employees in the documented programme or operating population; country, role and eligibility conditions retained.

Explore The Economy

The following articles provide wider sector context. They are not necessarily coverage of this specific entity or an endorsement by it.

Novartis AG’s incorporation in February 1996 and the Ciba-Geigy/Sandoz merger in December 1996 are distinct milestones. The Sandoz generics and biosimilars business was spun off on 3 October 2023; the current Novartis group focuses on innovative medicines. References: 20-F; 20-F; 20-F.